A traditional herbal medicinal product used to relieve the symptoms of the common cold and influenza type infections based on traditional use only.

For oral administration.

Adults, elderly and children over 12 years: take one tablet three times a day.

This product is not intended for children below 12 years.

Start at first signs of common cold. Do not use the medicinal product for more than 10 days.

If symptoms worsen during the use of the product or persist for more than 10 days, a doctor or a qualified healthcare practitionershould be consulted.

Hypersensitivity to the active substance or to plants of the Asteraceae (Compositae) family. Because of its immunostimulating activity, Echinacea must not be used in cases of progressive systemic disorders (tuberculosis, sarcoidosis), autoimmune diseases (e.g.: collagenoses, multiple sclerosis), immunodeficiencies (e.g.:HIV infection; AIDS), immunosuppression (e.g.: oncological cytostatic therapy; history of organ or bone marrow transplant), and diseases of the white blood cell system (e.g.: agranulocytosis, leukemias) allergic diathesis (e.g.: urticaria, atopic dermatitis, asthma).

Children under 12 years of age

Do not exceed the stated dose.

If the condition worsens, or high fever occurs during the use of this product, or if symptoms persist for more than 10 days, a doctor or qualified healthcare practitioner should be consulted.

This formulation is not suitable for children under 12 years of age.

Keep out of the sight and reach of children

There is a possible risk of anaphylactic reactions in atopic patients. Atopic patients should consult their doctor before using Echinacea

Not to be used concomitantly with immunosuppressant medications such as ciclosporin and methotrexate.

In the absence of sufficient data the use in pregnancy and lactation is not recommended.

Limited data (several hundreds of exposed pregnancies) indicate no adverse effects of Echinacea on pregnancy or on the health of the foetus/newborn child. Data concerning the immune system of the newborn child are not available. To date, no other relevant epidemiological data are available. The potential risk for humans is unknown.

No studies on the effects on the ability to drive and use machines have been performed.

Hypersensitivity reactions (rash, urticaria, Stevens-Johnson Syndrome, angioedema of the skin, Quincke edema, bronchospasm with obstruction, asthma and anaphylactic shock) may occur.

Echinacea can trigger allergic reactions in atopic patients. Association with autoimmune diseases (encephalitis disseminata, erythema nodosum, immunothrombocytopenia, Evans Syndrome, Sjö gren syndrome with renal tubular dysfunction) has been reported.

Leucopenia may occur in long-term use (more than 8 weeks).

The frequency is not known.

If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted..

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.

No case of overdose has been reported.

No relevant pharmacokinetic data are available.

No relevant pharmacokinetic data are available

Tests on reproductive toxicity, genotoxicity and on carcinogenicity have not been performed with Echinacea purpurea root.

Not applicable.

HDPE bottles

30 months

Glass bottles

36 months

Store below 25° C

HDPE bottle with tamper evident closure and foam wad. Printed card outer carton containing Patient Information Leaflet.

or

Ph Eur type III glass bottles with polypropylene closure incorporating an induction heat seal liner. Printed card outer carton containing Patient Information Leaflet.

Pack sizes of 30, 60, 90, 120, and 180 tablets. Not all pack sizes may be marketed.

No special requirements.